Simcere Zaiming and TargetRx Team Up to Develop TGRX-326 for Non-Small Cell Lung Cancer
Shots:
- Simcere Zaiming and Shenzhen TargetRx have entered into a collaboration agreement to develop TGRX-326 for cancer treatment
- Under the agreement, Simcere Zaiming secures exclusive rights to commercialize TGRX-326 in Mainland China. TargetRx is entitled to receive initial >$20M and will also compensate Simcere Zaiming for promotional services
- TGRX-326 is a small molecule ALK/ROS1 dual receptor tyrosine kinase inhibitor developed by TargetRx. It showed robust anti-tumor effectivess, safety and blood-brain barrier penetration, benefiting NSCLC patients with brain metastases
Ref: Simcere Zaiming | Image: Simcere Zaiming
Related Post:- The NMPA Approves Simcere Zaiming’s Enlituo (Biosimilar, Cetuximab Beta) as a 1L Treatment for Metastatic Colorectal Cancer (mCRC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
